LAVA Therapeutics B.V. [•] Common Shares, Nominal Value €0.12 Underwriting AgreementUnderwriting Agreement • March 18th, 2021 • LAVA Therapeutics BV • Pharmaceutical preparations • New York
LAVA Therapeutics B.V., a private company with limited liability organized under the laws of The Netherlands (besloten vennootschap met beperkte aansprakelijkheid) that is expected to convert into a public limited company organized under the laws of The Netherlands (naamloze vennootschap) at or immediately prior to the closing of the public offering of the Common Shares (as defined below) contemplated hereby (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] common shares, nominal value €0.12 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] common shares of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Common Shares”. The common shares of the Company to be outstanding after giving effect to the sa
e LAVA THERAPEUTICS N.V.$50,000,000Common StockEQUITY DISTRIBUTION AGREEMENTDated: April 11, 2022Equity Distribution Agreement • April 12th, 2022 • LAVA Therapeutics NV • Pharmaceutical preparations • New York
INDEMNIFICATION AGREEMENT between [name] as the Officer and LAVA Therapeutics N.V. as the CompanyIndemnification Agreement • March 18th, 2021 • LAVA Therapeutics BV • Pharmaceutical preparations
ContractLicense and Assignment Agreement • March 2nd, 2021 • LAVA Therapeutics BV • Pharmaceutical preparations
[***] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
DEED OF ISSUE LAVA THERAPEUTICS N.V.LAVA Therapeutics BV • January 25th, 2021 • Pharmaceutical preparations
LAVA Therapeutics N.V., a public company with limited liability, having its corporate seat in Utrecht (address: Yalelaan 60, 3584 CM Utrecht, trade register number: 65335740) (the “Company”).
EXECUTION COPY AMENDED AND RESTATED SHAREHOLDERS AGREEMENT BETWEEN DATED 15 SEPTEMBER 2020Shareholders Agreement • March 18th, 2021 • LAVA Therapeutics BV • Pharmaceutical preparations
All parties to this Agreement are together referred to as the Parties and each individually also as a Party. The parties mentioned under (1) through (13) are hereinafter collectively referred to as the Shareholders.
RESEARCH COLLABORATION AND LICENCE AGREEMENTResearch Collaboration and Licence Agreement • March 2nd, 2021 • LAVA Therapeutics BV • Pharmaceutical preparations
THIS RESEARCH COLLABORATION AND LICENCE AGREEMENT (the “Agreement”) dated as of May 13, 2020 (“Effective Date”) is entered into between Lava Therapeutics B.V., a limited liability company incorporated under the laws of the Netherlands, with offices at Yalelaan 60, 3584CM, Utrecht, The Netherlands (“LAVA”), and JANSSEN Biotech, Inc., a Pennsylvania corporation, with offices at 800 Ridgeview Drive, Horsham, PA 19044, USA. (“JANSSEN”).
ContractExclusive License Agreement • September 30th, 2022 • LAVA Therapeutics NV • Pharmaceutical preparations • New York
CERTAIN CONFIDENTIAL INFORMATION IN THIS EXHIBIT HAS BEEN OMITTED AND REPLACED WITH “[***]” BECAUSE IT IS NOT MATERIAL AND IS INFORMATION THAT THE COMPANY TREATS AS PRIVATE OR CONFIDENTIAL.
CLINICAL SUPPLY AGREEMENT by and betweenSupply Agreement • April 11th, 2023 • LAVA Therapeutics NV • Pharmaceutical preparations • New York
This Clinical Supply Agreement (this “Agreement”) is entered into as of January 27, 2023 (the “Effective Date”), by and between Seagen Inc., a Delaware corporation, having a place of business at 21823 30th Drive S.E., Bothell, WA 98021, United States (“Seagen”), and Lava Therapeutics N.V., a Netherlands public limited company (naamloze vennootschap) having an address at Yalelaan 60, 3584 CM Utrecht, the Netherlands (“Lava”). Seagen and Lava are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
